Brief: Centogene, Agios Expand Partnership For Clinical Development Of Pyrukynd (Mitapivat) To Treat Children With Rare Blood Disease

Crown LiquidationCo NV in liquidatie

13/06/2022 11:36

June 13 (Reuters) - Centogene NV  39K.MU :
    * CENTOGENE AND AGIOS EXPAND PARTNERSHIP FOR CLINICAL
DEVELOPMENT
OF PYRUKYND® (MITAPIVAT) TO TREAT CHILDREN WITH RARE BLOOD
DISEASE
    * CENTOGENE NV - EXPANDED COLLABORATION TO INCLUDE PHASE 3
ACTIVATE-KIDS AND ACTIVATE-KIDST STUDIES
    * CENTOGENE NV - AGIOS WILL BE COORDINATING AND BEARING
COSTS FOR
PROGRAMS; OTHER FINANCIAL DETAILS WERE NOT DISCLOSED

Source text for Eikon:  ID:nGNX4c2pPD 
Further company coverage:  39K.MU 

 ((Reuters.Briefs@thomsonreuters.com;))